LAS VEGAS, Aug. 23, 2006 (PRIMEZONE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs, is pleased to announce it is strengthening its business development capability with the promotion of Kristi Eads, who proudly received her law degree last month, to Vice President of Business Development.
Eads has been has been with Samaritan since 2000 serving as Vice President of Investor Relations since January 2004. In her former position, Eads was primarily responsible for overseeing all communications with the investment community, public and private. In her new role as Vice President of Business Development, Eads will work with Samaritan's business development team by focusing her efforts on in-licensing and partnering opportunities to grow and advance Samaritan's product pipeline.
"My goal is to increase shareholder value by helping Samaritan identify, evaluate and optimize its financial and business development opportunities. I am enthusiastic about Samaritan's technology and its potential in the marketplace," Eads said.
Eads obtained her juris doctorate from Concord University and has a bachelor of arts from the University of Oregon.
"Kristi has consistently dedicated herself to Samaritan's growth and we look forward to her enthusiasm for growth being directed to Samaritan's main objective of in-licensing approved drugs and the partnering of Samaritan's innovative pipeline," commented Dr. Janet Greeson, CEO of Samaritan.
Samaritan Pharmaceuticals: "We LIV....to Save Lives."
Samaritan is a small-cap Biotech, driven to discover, develop and commercialize innovative therapeutics' for AIDS, Alzheimer's, Cancer and Heart disease patients. Look at www.samaritanpharma.com. Please register on Website so we can notify you of upcoming conference calls, news and events.
The Samaritan Pharmaceuticals Inc. logo is available at http://www.primezone.com/newsroom/prs/?pkgid=2670
Disclaimer
The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 13, 2006. The company undertakes no duty to update forward-looking statements.